Skip to main content

Type of Educational Institution Attended Linked to Health Outcomes

Medically reviewed by Carmen Pope, BPharm. Last updated on June 19, 2024.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, June 19, 2024 -- The type of educational institution attended is associated with multiple health outcomes in midlife, according to a study published online June 18 in the Journal of Epidemiology & Community Health.

Keyao Deng, from University College London, and colleagues examined associations between the type of high school or university attended and 10 health outcomes that capture cardiometabolic risks, physical capabilities, and cognitive function at age 46 years using data from 8,107 participants in the 1970 British Cohort Study.

The researchers identified associations for private school and higher-status university with favorable health outcomes. Associations between private school attendance and cardiometabolic risks persisted after adjustment for potential confounders; the associations between higher-status university attendance and cognitive function persisted, while associations with other outcomes were mainly attenuated. Private school attendance was associated with a 0.14 standard deviation lower body mass index after full adjustment, and higher-status university attendance was associated with a 0.16 standard deviation better memory recall.

"We found that higher-status institution attendance was associated with better subsequent health in mid-adulthood, using multiple objective health measures," the authors write. "The type of education might be a factor contributing to the education-health relationship."

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million

TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...

Patient–Primary Care Provider Language Concordance Tied to Better Outcomes

TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...

Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care

TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.